Evidence map›Paper›PMID 38235904›Full record

Observational studyJournal of medical virology2024

SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.

Alexi Vasbinder, Kishan Padalia, Ian Pizzo, Kristen Machado, Tonimarie Catalan, Feriel Presswalla, Elizabeth Anderson, Anis Ismail, Christina Hutten, Yiyuan Huang and 24 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07466524 (suPAR ≥6 ng/mL for Predicting Severe Respiratory Failure in U.S. Adults Hospitalized With COVID 19), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07466524 completednot on this map

suPAR ≥6 ng/mL for Predicting Severe Respiratory Failure in U.S. Adults Hospitalized With COVID 19 (suPAR US The Michigan Cohort Heterogeneity Study)

TypeobservationalSponsorViroGates A/SRan2020 to 2022Enrolled367ConditionsCOVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress SyndromeArmssuPARnostic® TurbiLatex Assay on Roche cobas c501
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Alexi VasbinderDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kishan PadaliaDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Ian PizzoDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kristen MachadoDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Tonimarie CatalanDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Feriel PresswallaDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Elizabeth AndersonDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Anis IsmailDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Christina HuttenDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Yiyuan HuangDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Pennelope BlakelyDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Tariq U AzamDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Hanna BerlinDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Rafey FerozeDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Christopher LauniusDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Chelsea MelocheDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Erinleigh MichaudDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Patrick O'HayerDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Michael PanDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Husam R ShadidDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Line Jee Hartmann RasmussenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Donald A RobertsDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Lili ZhaoDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Mousumi BanerjeeDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Venkatesh MurthyDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Sven H LoosenClinic for Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany.
Athanasios ChalkiasInstitute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7634-4665
Frank TackeDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Jochen ReiserDepartment of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Jesper Eugen-OlsenDepartment of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Rodica Pop-BusuiDivision of Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Salim S HayekDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
ISIC investigators

Funding

TRAINING IN MOLECULAR AND CELLULAR CARDIOLOGYT32HL007853 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David J. Pinsky · 1996 to 2026
$11.6M
NIDDK Diabetic Foot Consortium Clinical Research UnitU01DK119083 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RODICA BUSUI (POP-BUSUI), Crystal Murray Holmes · 2018 to 2026
$5.5M
Role of SuPAR in the Intersection between Cardiovascular and Kidney DiseaseR01HL153384 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAYEK, SALIM · 2020 to 2024
$2.5M
Effects of Fish Oil ± Salsalate on the Omega-3 Index and the Circulating Lipodome of Omega-3 Polyunsaturated Fatty Acid Metabolites in Patients with Type 2 Diabetes and Diabetic NeuropathyR01DK126837 · NIDDK · UNIVERSITY OF IOWA · PI BUSUI (POP-BUSUI), RODICA, YOREK, MARK A. · 2022 to 2025
$2.5M
Extracorporeal SuPAR Extraction to Prevent COVID-19-associated Acute Kidney InjuryR01DK128012 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HAYEK, SALIM · 2021 to 2021
$327k
NHLBI NIH HHS R01 HL153384NHLBI NIH HHS T32 HL007853NIDDK NIH HHS R01 DK128012NIDDK NIH HHS U01 DK119083
6 · The paper itself

Abstract

Severe coronavirus disease 2019 (COVID-19) is a hyperinflammatory syndrome. The biomarkers of inflammation best suited to triage patients with COVID-19 are unknown. We conducted a prospective multicenter observational study of adult patients hospitalized specifically for COVID-19 from February 1, 2020 to October 19, 2022. Biomarkers measured included soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein, interleukin-6, procalcitonin, ferritin, and D-dimer. In-hospital outcomes examined include death and the need for mechanical ventilation. Patients admitted in the United States (US, n = 1962) were used to compute area under the curves (AUCs) and identify biomarker cutoffs. The combined European cohorts (n = 1137) were used to validate the biomarker cutoffs. In the US cohort, 356 patients met the composite outcome of death (n = 197) or need for mechanical ventilation (n = 290). SuPAR was the most important predictor of the composite outcome and had the highest AUC (0.712) followed by CRP (0.642), ferritin (0.619), IL-6 (0.614), D-dimer (0.606), and lastly procalcitonin (0.596). Inclusion of other biomarkers did not improve discrimination. A suPAR cutoff of 4.0 ng/mL demonstrated a sensitivity of 95.4% (95% CI: 92.4%-98.0%) and negative predictive value (NPV) of 92.5% (95% CI: 87.5%-96.9%) for the composite outcome. Patients with suPAR < 4.0 ng/mL comprised 10.6% of the cohort and had a 0.8% probability of the composite outcome. Applying this cutoff to the validation cohort yielded a sensitivity of 93.8% (90.4%-96.7%) and NPV of 95.5% (93.1%-97.8%) for the composite outcome. Among commonly measured biomarkers, suPAR offered stronger discriminatory ability and may be useful in triaging low-risk patients with COVID-19.

Indexed as

COVID-19Receptors, Urokinase Plasminogen ActivatorAdultBiomarkersFerritinsHumansInflammationProcalcitoninPrognosisProspective StudiesBiomarkersFerritinsProcalcitoninReceptors, Urokinase Plasminogen ActivatorC-reactive proteinCRPinfectioninterleukin-6risk predictionSARS-CoV-2soluble urokinase plasminogen activator receptorSuPARtriage

Identifiers

PMID38235904
PMCPMC10829525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.